Clinical Characteristics and Responses of Patients with Relapsed or Refractory High-Grade B-Cell Lymphoma Treated with Loncastuximab Tesirine in the Lotis-2 Clinical Trial
Juan Pablo Alderuccio(Sylvester Comprehensive Cancer Center), Paolo F. Caimi(University Hospitals Seidman Cancer Center), John Radford(Manchester Academic Health Science Centre), Eric Yu(Adc Therapeutics (Switzerland)), Brian Hess(Washington University in St. Louis), Carmelo Carlo‐Stella(Humanitas University), Anastasios Stathis(Princess Margaret Cancer Centre), Weiyun Z. Ai(City College of San Francisco), Kirit M. Ardeshna(UCL Biomedical Research Centre), David Ungar, Brad S. Kahl(UW Health University Hospital), Turk Kilavuz, Matthew A. Lunning(University of Nebraska Medical Center), Pier Luigi Zinzani(Istituto di Ematologia di Bologna), Melhem Solh(Johns Hopkins Hospital), Yajuan Qin, Mehdi Hamadani(Medical College of Wisconsin)
Cited by 3
Related Papers
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2013|1.7k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
|New England Journal of Medicine|2014|1.1k
Advanced pancreatic carcinoma: current treatment and future challenges
|Nature Reviews Clinical Oncology|2010|791